medecolМедицина и экологияMedicine and ecology2305-60452305-6053Карагандинский медицинский университет10.59598/ME-2305-6045-2024-113-4-68-76medecol-802Research ArticleКЛИНИЧЕСКАЯ МЕДИЦИНАCLINICAL MEDICINEДиагностические и прогностические биомаркеры при идиопатической легочной артериальной гипертензииDiagnostic and prognostic biomarkers at idiopathic pulmonary arterial hypertensionНурписоваT. T.NurpissovaT. T.

Тогжан Толегенкызы Нурписова – докторантр; врач-кардиолог

100008, г. Караганда, ул. Гоголя, 40

010000, г. Астана, район Есиль, ул. Е495 №2

Togzhan Tolegenkyzy Nurpissova – PhD student; cardiologist

100008, Karaganda, Gogol str., 40

010000, Astana city, Yesil district, E495 str. No.2

togzhan.tolegenkyzy@mail.ruТайжановаД. Ж.TaizhanovaD. Zh.

100008, г. Караганда, ул. Гоголя, 40

100008, Karaganda, Gogol str., 40

info@qmu.kzАбильдиноваГ. Ж.AbildinovaG. Zh.

010000, г. Астана, район Есиль, ул. Е495 №2

010000, Astana city, Yesil district, E495 str. No.2

kense@bmc.mcudp.kzНАО «Медицинский университет Караганды»; Больница Медицинского Центра Управления Делами Президента Республики КазахстанКазахстанNon-commercial joint stock company «Karaganda Medical University»; Medical Center Hospital of the President’s Affairs Administration of the Republic of KazakhstanKazakhstanНАО «Медицинский университет Караганды»КазахстанNon-commercial joint stock company «Karaganda Medical University»KazakhstanБольница Медицинского Центра Управления Делами Президента Республики КазахстанКазахстанMedical Center Hospital of the President’s Affairs Administration of the Republic of KazakhstanKazakhstan202422012025046876Copyright © Нурписова T.T., Тайжанова Д.Ж., Абильдинова Г.Ж., 20242024Нурписова T.T., Тайжанова Д.Ж., Абильдинова Г.Ж.Nurpissova T.T., Taizhanova D.Z., Abildinova G.Z.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://medecol.qmu.kz/jour/article/view/802

Введение. Идиопатическая легочная артериальная гипертензия (ИЛАГ) – представляет собой подтип ЛАГ, характеризующийся прогрессирующим увеличением легочного сосудистого сопротивления (ЛСС), что может привести к правожелудочковой сердечной недостаточности и даже смертности. Цель исследования – изучение уровня С-реактивного белка (СРБ), эндотелина-1 (ЭТ-1) и интерлейкина-6 (ИЛ-6) у пациентов с ИЛАГ, а также оценка их взаимосвязи с клиническими и гемодинамическими показателями.Материалы и методы. Экспрессию СРБ, ЭТ-1 и ИЛ-6 в образцах сыворотки пациентов с ИЛАГ (n=53) и контрольной группы (n=52) соответствующего возраста/пола определяли с помощью иммуноферментного анализа (ИФА). У пациентов с ИЛАГ изучены демографические, клинические характеристики и гемодинамические показатели по данным катетеризации правых отделов сердца (КПОС).Результаты и обсуждение. У пациентов с ИЛАГ средний возрастной диапазон составил 35.0–51.0 года, из них женщин 46 (86,8%), а в контрольной группе 31.0–42.0 года, женщин было 46 (88,5%). ЭТ-1 (p <.016) и ИЛ-6 (p <.001) были увеличены у пациентов с ИЛАГ по сравнению с контрольной группой, тогда как уровень СРБ (p = .270) не отличался в двух группах. Между тем, ЭТ-1 положительно коррелировал со средним давлением в правом предсердии (r = .728, p <.001) и легочно-сосудистым сопротивлением (r = .360, p = .008), тогда как ИЛ-6 положительно коррелировал с функциональным классом сердечной недостаточности по классификации New York Heart Association (NYHA FC).Заключение. ИЛ-6 и ЭТ-1 могут быть включены в диагностический алгоритм оценки тяжести и прогнозирования заболевания.

Introduction. Idiopathic pulmonary arterial hypertension (IPAH) is a subtype of pulmonary arterial hypertension (PAH). IPAH is characterized by a progressive increase in pulmonary vascular resistance (PVR), which can lead to right ventricular heart failure and even mortality. The aim was to study the levels of C-reactive protein (CRP), endothelin-1 (ET-1) and interleukin-6 (IL-6) in patients with IPAH, as well as to assess their relationship with clinical and hemodynamic parameters.Materials and methods. Expression of CRP, ET-1 and IL-6 in blood serum samples of patients with IPAH (n=53) and control group (n=52) of the appropriate age/gender was determined using enzyme immunoassay (ELISA). Demographic, clinical characteristics and hemodynamic parameters were studied in patients with IPAH according to catheterization of the right heart (CRH).Result and discussion. The average age range of patients with IPAH was 35.0-51.0 years, there were 46 (86.8%) women in this group. The average age of the participants in the control group was 31.0-42.0 years, there were 46 (88.5%) women. The levels of ET-1 (p < .016) and IL-6 (p < .001) were higher in patients with IPAH compared to patients in the control group, whereas the level of CRP (p = .270) was no different. Meanwhile, the level of ET-1 positively correlated with the average pressure in the right atrium (r = .728, p < .001) and pulmonary vascular resistance (r = .360, p = .008), while IL-6 positively correlated with the functional class of heart failure according to the classification of the New York Heart Association (NYHA FC).Conclusion. Levels of IL-6 and ET-1 can be included in the diagnostic algorithm for assessing the severity and prognosis of the disease.

идиопатическая легочная артериальная гипертензияс-реактивный белокэндотелин-1интерлейкин -6idiopathic pulmonary arterial hypertensionc-reactive proteinendothelin-1interleukin-6ReferencesBanecki K. M. R. M. Endothelin-1 in Health and Disease /K. M. R. M. Banecki, K. A. Dora //Int. J. Mol. Sci. – 2023. – V. 24 (14). – P. 11295.Banecki K. M. R. M. Endothelin-1 in Health and Disease /K. M. R. M. Banecki, K. A. Dora //Int. J. Mol. Sci. – 2023. – V. 24 (14). – P. 11295.Chen J. Y. Elevated interleukin-6 levels predict clinical worsening in pediatric pulmonary arterial hypertension /J. Y. Chen, M. Griffiths, J. Yang //J. Pediatr. – 2020. – V. 223. – P. 164-169.Chen J. Y. Elevated interleukin-6 levels predict clinical worsening in pediatric pulmonary arterial hypertension /J. Y. Chen, M. Griffiths, J. Yang //J. Pediatr. – 2020. – V. 223. – P. 164-169.Dorfmuller P. Inflammation in pulmonary arterial hypertension /P. Dorfmuller, F. Perros, K. Balabanian //Eur. Respir. J. – 2003. – V. 22 (2). – P. 358-363.Dorfmuller P. Inflammation in pulmonary arterial hypertension /P. Dorfmuller, F. Perros, K. Balabanian //Eur. Respir. J. – 2003. – V. 22 (2). – P. 358-363.Giaid A. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension /A. Giaid, M. Yanagisawa, D. Langleben //N. Engl. J. Med. – 1993. – V. 328 (24). – P. 1732-1739.Giaid A. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension /A. Giaid, M. Yanagisawa, D. Langleben //N. Engl. J. Med. – 1993. – V. 328 (24). – P. 1732-1739.Hashimoto-Kataoka T. Interleukin-6/ interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension / T. Hashimoto-Kataoka, N. Hosen, T. Sonobe //Proc. Natl. Acad. Sci. United States America. – 2015. – V. 112 (20). – P. 2677-2686.Hashimoto-Kataoka T. Interleukin-6/ interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension / T. Hashimoto-Kataoka, N. Hosen, T. Sonobe //Proc. Natl. Acad. Sci. United States America. – 2015. – V. 112 (20). – P. 2677-2686.Hernandez-Sanchez J. Clinical trial protocol for TRANSFORM-UK: a therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension /J. Hernandez-Sanchez, L. Harlow, C. Church //Pulmonary Circ. – 2017. – V. 8(1). – 2045893217735820.Hernandez-Sanchez J. Clinical trial protocol for TRANSFORM-UK: a therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension /J. Hernandez-Sanchez, L. Harlow, C. Church //Pulmonary Circ. – 2017. – V. 8(1). – 2045893217735820.Hirsch K. Circulating markers of inflammation and angiogenesis and clinical outcomes across subtypes of pulmonary arterial hypertension /K. Hirsch, S. Nolley, D. D. Ralph //J. Heart Lung. Transplant. – 2023. – V. 42 (2). – P. 173-182.Hirsch K. Circulating markers of inflammation and angiogenesis and clinical outcomes across subtypes of pulmonary arterial hypertension /K. Hirsch, S. Nolley, D. D. Ralph //J. Heart Lung. Transplant. – 2023. – V. 42 (2). – P. 173-182.Humbert M. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension /M. Humbert, G. Kovacs, M. M. Hoeper //Eur. Heart J. – 2022. – V. 38. – P. 3618-3731.Humbert M. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension /M. Humbert, G. Kovacs, M. M. Hoeper //Eur. Heart J. – 2022. – V. 38. – P. 3618-3731.Kazimierczyk R. Platelet sTWEAK and plasma IL-6 are associated with 18F-fluorodeoxyglucose uptake in right ventricles of patients with pulmonary arterial hypertension: a pilot study /R. Kazimierczyk, P. Szumowski, S. Nekolla //Adv. Clin. Exp. Med. – 2022. – V. 31 (9). – P. 991-998.Kazimierczyk R. Platelet sTWEAK and plasma IL-6 are associated with 18F-fluorodeoxyglucose uptake in right ventricles of patients with pulmonary arterial hypertension: a pilot study /R. Kazimierczyk, P. Szumowski, S. Nekolla //Adv. Clin. Exp. Med. – 2022. – V. 31 (9). – P. 991-998.Ng D. P. An IL-6 haplotype on human chromosome 7p21 confers risk for impaired renal function in type 2 diabetic patients /D. P. Ng, S. Nurbaya, S. H. Ye //Kidney Int. – 2008. – V. 74 (4). – P. 521-527.Ng D. P. An IL-6 haplotype on human chromosome 7p21 confers risk for impaired renal function in type 2 diabetic patients /D. P. Ng, S. Nurbaya, S. H. Ye //Kidney Int. – 2008. – V. 74 (4). – P. 521-527.Quarck R. C-Reactive Protein: A new predictor of adverse outcome inpulmonary arterial hypertension /R. Quarck, T. Nawrot, B. Meyns //J. Am. Coll. Cardiol. – 2009. – V. 53. – P. 1211-1218.Quarck R. C-Reactive Protein: A new predictor of adverse outcome inpulmonary arterial hypertension /R. Quarck, T. Nawrot, B. Meyns //J. Am. Coll. Cardiol. – 2009. – V. 53. – P. 1211-1218.Rozengurt N. Localization of endothelin-like immunoreactivity in airway epithelium of rats and mice /N. Rozengurt, D. R. Springall, J. M. Polak //J. Pathol. – 1990. – V. 160. – P. 5-8.Rozengurt N. Localization of endothelin-like immunoreactivity in airway epithelium of rats and mice /N. Rozengurt, D. R. Springall, J. M. Polak //J. Pathol. – 1990. – V. 160. – P. 5-8.Rubens C. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary /C. Rubens, R. Ewert, M. Halank //Chest. – 2001. – V. 120 (5). – P. 1562-1569.Rubens C. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary /C. Rubens, R. Ewert, M. Halank //Chest. – 2001. – V. 120 (5). – P. 1562-1569.Selimovic N. Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension /N. Selimovic, C. H. Bergh, B. Andersson //Eur. Respir. J. – 2009. – V. 34 (3). – P. 662-668.Selimovic N. Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension /N. Selimovic, C. H. Bergh, B. Andersson //Eur. Respir. J. – 2009. – V. 34 (3). – P. 662-668.Shao D. The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension /D. Shao, J. E. S. Park, S. J. Wort //Pharmacological Research. – 2011. – V. 63. – P. 504-511.Shao D. The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension /D. Shao, J. E. S. Park, S. J. Wort //Pharmacological Research. – 2011. – V. 63. – P. 504-511.Simpson C. E. Cellular sources of interleukin-6 and associations with clinical phenotypes and outcomes in pulmonary arterial hypertension /C. E. Simpson, J. Y. Chen, R. L. Damico //Eur. Respir. J. – 2020. – V. 55 (4). – 1901761.Simpson C. E. Cellular sources of interleukin-6 and associations with clinical phenotypes and outcomes in pulmonary arterial hypertension /C. E. Simpson, J. Y. Chen, R. L. Damico //Eur. Respir. J. – 2020. – V. 55 (4). – 1901761.Soon E. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension /E. Soon, A. M. Holmes, C. M. Treacy //Circulation. – 2010. – V. 122 (9). – P. 920-927.Soon E. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension /E. Soon, A. M. Holmes, C. M. Treacy //Circulation. – 2010. – V. 122 (9). – P. 920-927.Taichman D. B. Epidemiology of pulmonary arterial hypertension /D. B. Taichman, J. Mande // Clin. Chest. Med. – 2013. – V. 34 (4). – P. 619-637.Taichman D. B. Epidemiology of pulmonary arterial hypertension /D. B. Taichman, J. Mande // Clin. Chest. Med. – 2013. – V. 34 (4). – P. 619-637.Vizza C. D. Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan /C. D. Vizza, C. Letizia, R. Badagliacca // Int. J. Cardiol. – 2013. – V. 167. – P. 220-224.Vizza C. D. Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan /C. D. Vizza, C. Letizia, R. Badagliacca // Int. J. Cardiol. – 2013. – V. 167. – P. 220-224.Wu W. H. Impact of pituitary-gonadal axis hormones on pulmonary arterial hypertension in men /W. H. Wu, P. Yuan, S. J. Zhang //Hypertension. – 2018. – V. 72 (1). – P. 151-158.Wu W. H. Impact of pituitary-gonadal axis hormones on pulmonary arterial hypertension in men /W. H. Wu, P. Yuan, S. J. Zhang //Hypertension. – 2018. – V. 72 (1). – P. 151-158.Xu W. J. Interleukin-6 and pulmonary hypertension: from physiopathology to therapy /W. J. Xu, Q. Wu, W. N. He //Front Immunol. – 2023. – V. 28 (14). – 1181987.Xu W. J. Interleukin-6 and pulmonary hypertension: from physiopathology to therapy /W. J. Xu, Q. Wu, W. N. He //Front Immunol. – 2023. – V. 28 (14). – 1181987.Yanagisawa M. A novel potent vasoconstrictor peptide produced by vascular endothelial cells /M. Yanagisawa, H. Kurihara, S. Kimura //Nature. – 1988. – V. 332. – P. 411-415.Yanagisawa M. A novel potent vasoconstrictor peptide produced by vascular endothelial cells /M. Yanagisawa, H. Kurihara, S. Kimura //Nature. – 1988. – V. 332. – P. 411-415.

The authors declare that there are no conflicts of interest present.